Syntekabio to Highlight its Cutting-edge AI-driven Discovery Solutions at BioTechX Company’s supercomputer-powered platforms find and optimize novel compounds, enable antibody and neoantigen prediction
DAEJEON, Rep. of Korea and New York, NY USA
|
September 06, 2024 08:30 AM Eastern Daylight Time
Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) based drug development company, today announced its participation at BioTechX USA, being held September 17-18, 2024 in Philadelphia, PA. Syntekabio is the Title Sponsor for the event and will give a keynote address and in-depth talk on its AI-driven solutions, as well as host a booth.
“We look forward to meeting with potential clients at BioTechX and discussing how our AI-driven technologies can improve and accelerate their R&D activities,” said Jongsun Jung, PhD, CEO of Syntekabio. “We recently announced our ‘Develop Now, Pay Later’ offer that enables clients to test the validity of a target protein of interest without incurring any upfront costs. In addition to identifying potential hits and optimizing small molecule leads, we also have strong capabilities in antibody and cancer neoantigen discovery. We are excited to have the opportunity to highlight these technologies at the conference.”
Meet us at BioTechX USA!
Syntekabio has several activities planned at the conference.
Schedule a meeting by clicking here or stop by our booth (#401) to meet the team and learn how our innovative AI-driven solutions can help solve your current pipeline challenges.
Don’t miss out on the latest insights in AI presented in our talks!
Tuesday, September 17th
9:20 AM - Keynote presentation
Addressing Data Scarcity in Drug Discovery with Physics-based AI Models
Jonathan Witztum, PhD, CTO, Syntekabio USA
5:05 PM – AI in drug discovery presentation
Flexible Molecular Docking for Neoantigen & Antibody Drug Prediction; Pre-Clinical
Application
Jongsun Jung, PhD, CEO, Syntekabio
Recently announced Develop Now, Pay Later offer – drug discovery with no upfront fees
Syntekabio’s Develop Now, Pay Later model enables pharmaceutical and biotechnology companies to test the validity of a target protein of interest without incurring any upfront costs. Should a project demonstrate viability, Syntekabio then employs its STB LaunchPad program, powered by its proprietary AI-driven DeepMatcher® technology platform, to deliver hits and optimized leads as well as IND-enabled candidates. The client only pays for the work once the agreed upon validated results are obtained. For more information about Syntekabio, STB LaunchPad and Develop Now, Pay Later, please click here.
Additional powerful tools enable novel antibody and cancer neoantigen prediction
Additionally, the company will highlight its in silico biologics platforms, Neo-ARSTM and Ab-ARSTM, which enable personalized or universal neoantigen cancer vaccine and novel antibody drug prediction, respectively. These cutting-edge solutions address complex challenges in drug discovery, equipping researchers with powerful tools to develop novel and effective therapeutics.
Syntekabio’s AI accesses over 10 billion known compounds as well as 1,400 in vitro/in vivo compatible drug targets covering over 70% of human diseases. This technology is powered by Syntekabio’s AI Bio-Supercom Center, which houses an immense infrastructure of 5,000 servers, 40,000 CPU cores, and 2,500 GPUs fueling the Company’s algorithms. The Company has a comprehensive suite of advanced proprietary tools designed to accelerate the drug discovery and development process.
About Syntekabio
Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The Company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio’s disease-agnostic physics-based platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The Company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications. Visit the Syntekabio website at www.syntekabio.com or follow the Company on LinkedIn for the latest updates.
Contact Details
Media inquiries US & Europe - MC Services AG
Laurie Doyle / Dr. Cora Kaiser
+1 339-832-0752
Company Website
